PLASMA-SAFE-SEQS
Ultra-sensitive NGS liquid biopsy technology
Our new Plasma-Safe-SeqS NGS technology can detect clinically relevant mutations in circulating tumor DNA (ctDNA) with sensitivity equivalent to our OncoBEAM digital PCR liquid biopsy from across a broader range of genomic regions.
OncoBEAM set the gold standard for ctDNA analysis as the most sensitive digital PCR approach available.(1) It has been used to detect subclonal resistance mutations, such as those in ESR1 for breast cancer patients on adjuvant aromatase inhibitor therapy who demonstrate endocrine resistance.(2)
With robust detection as low as 0.03%* mutant allele frequency (MAF), Plasma-Safe-SeqS ensures reliable molecular information for real-time therapy selection as well as monitoring of tumor response.
The data in the figure below shows the robust accuracy at low allelic frequencies observed for Plasma-Safe-SeqS and demonstrates the advantages of using focused panels for defined clinical purposes.(3)
*For input of 20,000 genomic equivalents
Citations
1.Diehl F, Li M, Dressman D, He Y, et al. Detection and Quantification of Mutations in the Plasma of Patients with Colorectal Tumors. Proc Natl Acad Sci USA. 2005. 102(45):16368-16373. doi: 10.1073/pnas.0507904102.
2. Spoerke, J. M. et al. (2016) Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant. Nat Commun. 7, 11579.
3. Rugo HS, Mayer E, Storniolo Anna Maria, Isaac C, et al. Palbociclib in combination with fulvestrant or tamoxifen as treatment for hormone receptor positive metastatic breast cancer with prior chemotherapy for advanced disease (TBCRC 035): A Phase II study with pharmacodynamic markers. Presented at the American Association of Cancer Research annual conference, Atlanta, Georgia. 2019. doi: 10.1158/1538-7445.AM2019-CT128.
Plasma-Safe-SeqS sensitivity has 99.2% agreement with OncoBEAMTM
This chart measures the mutant allele frequency of Plasma-Safe-SeqS with OncoBEAMTM technology for ESR1, PIK3CA, AKT1, ESR1, PIK3A, and AKT1 clinical samples and shows that Plasma-Safe-SeqS has a 99.2 percent positive agreement out of 100 for mutant allele frequency, also known as MAF, sensitivity.
Ultra-sensitive NGS Liquid Biopsy Technology
Our cost-effective and industry-leading ultra-sensitive NGS liquid biopsy solutions identify tumor mutations across cancer types for a range of intended uses:
- Inform therapy selection
- Dynamically monitor tumor response
- Identify molecular mediators of resistance
- Detect minimal residual disease (MRD) at a variant level

Ultra-sensitive Plasma-Safe-SeqS Panels
With Plasma-Safe-SeqS, 100% of the starting molecules are analyzed, which isn’t always the case with other methods or technologies. This chart shows that with Plasma-Safe-SeqS, the input molecules are not lost along the sequencing process like they commonly can be with other methods or technologies. The chart shows the sample input of benign molecules and mutant molecules remain intact throughout sample amplification, multiplexing, dilution, purification, and quantification. The second part of the chart shows that 40% of molecules could be lost during sample preparation prior to ligation/hybrid-capture based next-generation sequencing (or NGS), which could lead to a false negative or inaccurate analysis.
Routine Clinical Testing: Plasma-Safe-SeqS vs Pan-Cancer NGS
This table compares Plasma-Safe-SeqS with other ctDNA NGS methods and measures sensitivity, sample volume, gene coverage, customization ability, and cost. Plasma-Safe-SeqS has a minor allele frequency (MAF) of >0.05% compared to an MAF of >1% for other methods. Sample volume for Plasma-Safe-SeqS is 2 mL of plasma compared to 8 mL of plasma. Gene coverage for Plasma-Safe-SeqS is clinically relevant, adjustable coverage compared to indiscriminate, fixed coverage of 40+ genes. Plasma-Safe-SeqS is high fidelity customizable, and other methods have a low capability to customize. Plasma-Safe-SeqS is cost efficient and other methods are high cost.